Skip to main content

El uso del pago por resultados para los fármacos: ¿Puede mejorar los incentivos para la innovación?

  • Chapter
Incentivos a la I+D+i de Medicamentos

Resumen

Recientemente ha habido un aumento del interés por los esquemas que incluyen un „pago por la medicación según resultados“ (Pollock, 2007) es decir, el „pago por resultados“ en vez del simple „pago por el medicamento“. Los pagadores de la asistencia sanitaria, sometidos a una gran presión, quieren saber que obtienen aquello por lo que pagan, es decir, un efecto „sobre la salud y beneficios para los pacientes“. Las compañías farmacéuticas no están dispuestas a aceptar unos precios que piensan que no reflejan el valor de innovación, derivado de sus costosas inversiones en I+D, que están aportando a los pacientes, al sistema de asistencia sanitaria y a la economía en sentido más amplio. El pago por los resultados obtenidos es una forma de „cuadratura del círculo“. Los pagadores saben que están obteniendo un valor. Las compañías farmacéuticas obtienen un retorno que incentiva las innovaciones futuras.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 44.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 59.95
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Bibliografía

  • Boggild M, Palace J, Barton P, Ben-Shlomo Y, Bregenzer T, Dobson C, et al. Multiple sclerosis risk sharing scheme: two year results of clinical cohort study with historical comparator. BMJ. 2009; 339: 4677.

    Article  Google Scholar 

  • Carlson JJ, Sullivan SD, Garrison LP, Neumann PJ, Veenstra DL. Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers. Health Policy. 2010;96(3):179–90.

    Article  PubMed  Google Scholar 

  • Cook JP, Vernon JA, Manning R. Pharmaceutical risk-sharing agreements. Pharmacoeconomics. 2008;26(7):551–6.

    Article  PubMed  Google Scholar 

  • de Pouvourville, G. “Risk-sharing agreements for innovative drugs: a new solution to old problems?” Eur J Health Econ. 2006; 7(3):155–7.

    Article  PubMed  Google Scholar 

  • Eckermann S, Willan AR. Expected value of information and decision making in HTA. Health Econ. 2007;16:195–209.

    Article  PubMed  Google Scholar 

  • Eckermann S, Willan AR. Globally optimal trial design for local decision making. Health Econ. 2009; 18:203–16.

    Article  PubMed  Google Scholar 

  • Lilford RJ. Response from chair of scientific advisory committee. BMJ. 2010;341:c3590.

    Article  Google Scholar 

  • McCabe C, Chilcott J, Claxton K, Tappenden P, Cooper C, Roberts J, et al. Continuing the multiple sclerosis risk sharing scheme is unjustified. BMJ. 2010;340:1786.

    Article  Google Scholar 

  • Moldrup C. No cure no pay. BMJ. 2005;330(7502):1262–4.

    Article  PubMed  Google Scholar 

  • Pollock A. Pricing Pills by the Results. New York Times; 14th July 2007.

    Google Scholar 

  • Puig-Peiró, R. Mestre-Ferrandiz J, Sussex J, Towse A. Literature review on Patient Access Schemes, Flexible Pricing Schemes and Risk Sharing Agreements for medicines. Podium presentation. ISPOR 14th Annual European Congress, Madrid, Spain: 5–8 November 2011. Disponible en http://www.ispor. org/research_pdfs/39/pdffiles/RS1.pdf [Consultado el 28 de noviembre de 2011]

    Google Scholar 

  • Raftery J. Multiple sclerosis risk sharing scheme: a costly failure. BMJ. 2010; 40:1672.

    Article  Google Scholar 

  • Richards RG. MS risk sharing scheme. Some clarification needed. BMJ. 2010;341:3589.

    Article  Google Scholar 

  • Scolding N. The multiple sclerosis risk sharing scheme. BMJ. 2010;340:2882.

    Article  Google Scholar 

  • SCRIP. NICE set to recommend Stelara for psoriasis. SCRIP World Pharmaceutical News. August 17th 2009.

    Google Scholar 

  • Sendi PP, Briggs AH. Affordability and cost-effectiveness: decision-making on the cost-effectiveness plane. Health Econ. 2001;10:675–80.

    Article  PubMed  CAS  Google Scholar 

  • Towse A. Value-based pricing, research and development, and patient access schemes. Will the United Kingdom get it right or wrong? Br J Clin Pharmacol. 2010;70(3):360–6.

    Article  PubMed  Google Scholar 

  • Towse A, Garrison LP Jr. Can’t get no satisfaction? Will pay-for-performance help? Toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical products. Pharmacoeconomics. 2010;28(2):93–102.

    Article  PubMed  Google Scholar 

  • Williamson S. Patient access schemes for high-cost cancer medicines. Lancet Oncol. 2010;11(2):111–2.

    Article  PubMed  Google Scholar 

  • Wlodarczyk JH, Cleland LG, Keogh AM, McNeil KD, Perl K, Weintraub RG, et al. Public funding of bosentan for the treatment of pulmonary artery hypertension in Australia: cost effectiveness and risk sharing. Pharmacoeconomics. 2006;24(9):903–15.

    Article  PubMed  Google Scholar 

Download references

Authors

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Healthcare Communications Iberica SL.

About this chapter

Cite this chapter

Towse, A., Garrison, L., Puig-Peiró, R. (2012). El uso del pago por resultados para los fármacos: ¿Puede mejorar los incentivos para la innovación?. In: Incentivos a la I+D+i de Medicamentos. Springer Healthcare, Madrid. https://doi.org/10.1007/978-84-938062-9-3_6

Download citation

  • DOI: https://doi.org/10.1007/978-84-938062-9-3_6

  • Publisher Name: Springer Healthcare, Madrid

  • Print ISBN: 978-84-938062-2-4

  • Online ISBN: 978-84-938062-9-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics